Inhibikase Therapeutics, Inc. (IKT)

NASDAQ: IKT · IEX Real-Time Price · USD
0.602
+0.002 (0.33%)
At close: Mar 21, 2023, 4:00 PM
0.610
+0.008 (1.40%)
After-hours: Mar 21, 2023, 4:08 PM EDT
0.33%
Market Cap 16.87M
Revenue (ttm) 61,818
Net Income (ttm) -18.82M
Shares Out 28.03M
EPS (ttm) -0.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 175,813
Open 0.602
Previous Close 0.600
Day's Range 0.602 - 0.644
52-Week Range 0.440 - 1.520
Beta 0.97
Analysts Sell
Price Target 6.12 (+916.61%)
Earnings Date Mar 30, 2023

About IKT

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib th... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 23, 2020
Employees 6
Stock Exchange NASDAQ
Ticker Symbol IKT
Full Company Profile

Financial Performance

In 2021, IKT's revenue was $3.10 million, an increase of 343.92% compared to the previous year's $698,468. Losses were -$14.79 million, 419.2% more than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for IKT stock is "Sell." The 12-month stock price forecast is $6.12, which is an increase of 916.61% from the latest price.

Price Target
$6.12
(916.61% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Inhibikase Therapeutics to Present at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders

BOSTON and ATLANTA , March 21, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor...

8 hours ago - PRNewsWire

Inhibikase Therapeutics to Host Virtual R&D Event on March 22, 2023

BOSTON and ATLANTA , March 16, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor...

5 days ago - PRNewsWire

Inhibikase Therapeutics Provides Interim Update on the '501' Bioequivalence Study of IkT-001Pro

Completed dosing of 3 of 4 planned cohorts; expect to complete study in the second quarter of 2023 BOSTON and ATLANTA , March 15, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inh...

6 days ago - PRNewsWire

Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Multiple System Atrophy

- Advancing model studies of IkT-148009 in MSA; early data has shown a substantial neuroprotective benefit in response to c-Abl inhibition by IkT-148009 – - MSA IND Opened, the 5th in the Company's hi...

1 week ago - PRNewsWire

Inhibikase Therapeutics to Present at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit

BOSTON and ATLANTA , Feb. 15, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor ...

1 month ago - PRNewsWire

Inhibikase Therapeutics Announces Closing of $10 Million Concurrent Registered Direct Offering and Private Placement Priced At a Premium to Market Under Nasdaq Rules

BOSTON and ATLANTA , Jan. 27, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor ...

1 month ago - PRNewsWire

Why Is Inhibikase Therapeutics (IKT) Stock Down 11% Today?

Inhibikase Therapeutics (NASDAQ: IKT) stock is falling on Thursday after the company announced a registered direct offering and private placement. Starting with the registered direct offering up 6,74...

1 month ago - InvestorPlace

Inhibikase Therapeutics Announces $10 Million Concurrent Registered Direct Offering and Private Placement Priced at a Premium to Market Under Nasdaq Rules

BOSTON and ATLANTA , Jan. 25, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor ...

1 month ago - PRNewsWire

Inhibikase Therapeutics Announces Publication Demonstrating Potential for c-Abl as a Key Therapeutic Target in Parkinson's Disease and Related Disorders

- Animal model studies highlight potential of the c-Abl inhibitor IkT-148009 to modify the course of Parkinson's Disease and Suppress Protein Pathology - BOSTON and ATLANTA , Jan. 25, 2023 /PRNewswire...

1 month ago - PRNewsWire

Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Parkinson's Disease

- Phase 2a '201' clinical trial will resume immediately at 50 and 100 mg doses- -Additional safety and pharmacokinetic information will be measured in healthy subjects at the 200 mg dose prior to impl...

1 month ago - PRNewsWire

Inhibikase Therapeutics Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro

BOSTON and ATLANTA , Dec. 12, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor ...

3 months ago - PRNewsWire

Inhibikase Therapeutics Provides Update to FDA Clinical Hold of IkT-148009 Programs

BOSTON and ATLANTA , Dec. 7, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or the "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibit...

3 months ago - PRNewsWire

Inhibikase Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference

BOSTON and ATLANTA, Nov. 22, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to ...

4 months ago - PRNewsWire

Inhibikase Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity

Company to host conference call and webcast on November 15, 2022 at 8:00am ET BOSTON and ATLANTA , Nov. 14, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company")...

4 months ago - PRNewsWire

Inhibikase Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022

BOSTON and ATLANTA , Nov. 8, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor t...

4 months ago - PRNewsWire

Inhibikase Therapeutics Announces FDA Clinical Hold on IkT-148009 Programs

BOSTON and ATLANTA , Nov. 7, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor t...

4 months ago - PRNewsWire

Inhibikase Therapeutics to Present at the Cambridge Healthtech Institute's Inaugural Neurodegeneration Targets Conference

BOSTON and ATLANTA , Oct. 12, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to...

5 months ago - PRNewsWire

Inhibikase Therapeutics to Present at the Grand Challenges in Parkinson's Disease Conference

BOSTON and ATLANTA , Sept. 21, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics t...

6 months ago - PRNewsWire

Inhibikase Therapeutics to Present Data from Phase 1/1b study of IkT-148009 at the Movement Disorders Society Congress

IkT-148009 was well-tolerated with high systemic exposure and persistent penetration into the central nervous system (CNS) in older and elderly healthy volunteers and Parkinson's patients No clinicall...

6 months ago - PRNewsWire

Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders

BOSTON and ATLANTA , Sept. 8, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to...

6 months ago - PRNewsWire

Inhibikase Therapeutics Appoints Gisele Dion to Board of Directors

BOSTON and ATLANTA , Sept. 1, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Par...

7 months ago - PRNewsWire

Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia

BOSTON and ATLANTA, Aug. 26, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to ...

7 months ago - PRNewsWire

Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2a '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease

BOSTON and ATLANTA , Aug. 23, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Par...

7 months ago - PRNewsWire

Inhibikase Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity

Company to host conference call and webcast on Monday, August 15, 2022, at 8:00am ET BOSTON and ATLANTA , Aug. 12, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Co...

7 months ago - PRNewsWire

Inhibikase Therapeutics to Report Second Quarter 2022 Financial Results on August 12, 2022

BOSTON and ATLANTA , Aug. 8, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Park...

8 months ago - PRNewsWire